{
    "organizations": [],
    "uuid": "a5ccca82251c105b37f71500f914b0401aa3c8d9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-arrowhead-pharmaceuticals-arrowhea/brief-arrowhead-pharmaceuticals-arrowhead-begins-dosing-in-phase-1-2-study-of-aro-hbv-idUSFWN1R90AE",
    "ord_in_thread": 0,
    "title": "BRIEF-Arrowhead Pharmaceuticals Arrowhead Begins Dosing In Phase 1/2 Study Of ARO-HBV",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 27 (Reuters) - Arrowhead Pharmaceuticals Inc:\n* ARROWHEAD BEGINS DOSING IN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ",
    "published": "2018-03-27T19:43:00.000+03:00",
    "crawled": "2018-03-28T19:01:45.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "arrowhead",
        "pharmaceutical",
        "inc",
        "arrowhead",
        "begin",
        "dosing",
        "phase",
        "study",
        "treatment",
        "chronic",
        "hepatitis",
        "b",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}